 |
 |
|
|
|
|
|
Sessions of Interest for the Upcoming 2022 Annual Meeting
|
|
|
|
|
|
| Plenary |
| 7:30 AM – 11:30 AM CST
|
|
|
|
|
What is the Optimal Multidisciplinary Team in 2022: Drafting for the Future
Moderator: Leonard G. Gomella, MD
Panelist(s): Michael S. Cookson, MD, MHA and Neal D. Shore, MD |
|
|
|
|
Women in Urologic Oncology: Past, Present and Future
Moderator(s): Eila Curlee Skinner, MD
Panelist(s): Cheryl Taylore Lee, MD, Sarah P. Psutka, MD, Sima Porten, MD, FACS, MPH, Kristen R. Scarpato, MD, MPH |
|
|
|
|
State-of-the-Art Lecture: PSMA Diagnostics and Theranostics
Presented By: William J. Aronson, MD
|
|
|
|
|
Best Prostate Biopsy Techniques in 2022
Moderator: Daniel Ari Barocas, MD, MPH
Panelist(s): Arvin George, MD, Benjamin T. Ristau, MD, Samir Taneja, MD, Kristen R. Scarpato, MD, MPH |
|
|
|
|
Final clinical results of pivotal trial of IL-15R&[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) CIS and Papillary Cohorts
Presented By: Mark Fleming, MD
|
|
|
|
|
Survivor Debate: Non-muscle Invasive Bladder Cancer Refractory to BCG: Cystectomy, Systemic immunotherapy, Intravesical Chemotherapy
Moderator(s): Tracy M. Downs, MD
Panelist(s): James Michael McKiernan, MD, Seth Paul Lerner, MD |
|
|
|
|
Management of Incidentally Discovered 3cm Solid Renal Mass Cancer
Moderator(s): Costas D. Lallas, MD
Panelist(s): Brian Robert Lane, MD,PhD,FACS, Lee Evan Ponsky, MD, Jaime Landman, MD |
|
|
|
|
|
|
| Plenary
|
| 1:00 PM – 4:50 PM CST
|
|
|
|
|
AUA Guidelines: Localized Prostate Cancer
Presented By: James A. Eastham, MD
Confederación Americana de Urología (CAU) Lecture: The Fine Borderline between High-risk, Locally-advanced and Oligometastatic Prostate Cancer
Presented By: Rafael Sanchez-Salas, MD
AUA Guidelines Update: Renal Mass
Presented By: Steven Charles Campbell, MD, PHD
|
|
|
|
|
|
|
|
|
|
Controversies in Urology Debate: Focal Ablation versus Active Surveillance in a 65M with GGG2, MRI Concordant Unilateral Prostate Cancer
Moderator(s): Kirsten Lynn Greene, MD, FACS, MS
Debater(s): Dipen J. Parekh, MD, and Robert Evan Reiter, MD UCLA |
|
|
|
|
|
|
| Bladder Cancer: Epidemiology & Evaluation I |
| 3:30 PM – 5:30 PM CST
|
|
|
|
|
Is a Restaging TURBT Necessary in High Risk Non-Muscle Invasive Bladder Cancer if the Initial TURBT Was Performed Using Blue Light?
Presented By: Muhannad Alsyouf, MD
|
|
|
|
|
|
|
|
|
| Prostate Cancer: Advanced (including Drug Therapy) I
|
| 10:30 - 11:45 AM CST
|
|
|
|
|
Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients With and Without Prior Local Therapy With Radical Prostatectomy or Radiotherapy
Presented By: D. Robert Siemens, MD
|
|
|
|
|
Long-term Safety of Darolutamide Among Patients With Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy
Presented By: Robert H. Jones, MD
|
|
|
|
|
|
| Society of Urologic Oncology
|
| 12:25 PM – 5:05 PM CST |
|
|
| Chair(s) Brian W. Cross, MD, and Stacy Loeb, MD, PHD, MSC |
|
|
|
|
|
|
|
| Prostate Cancer: Localized: Active Surveillance |
| 10:30 AM –11:45 AM CST
|
|
|
|
|
Active surveillance for low-risk prostate cancer: time trends and variation in the AUA Quality (AQUA) Registry
Presented By: Matthew R. Cooperberg, MD, MPH
|
|
|
|
|
|
| Podium: Late-breaking Abstract I - Cancer & BPH |
| 1:00 PM – 3:00 PM CST
|
|
|
|
|
| Moderator(s): Aria Olumi, MD, David Jarrard, MD, Christian Gratzke, MD |
|
|
|
|
|
| AUA Bladder Cancer Forum |
| 2:00 PM – 5:00 PM CST
|
|
|
|
|
| Chairs: Ashish Kamat, MD, MBBS, and Sima Porten, MD, MPH |
|
|
|
|
|
| Prostate Cancer: Advanced (including Drug Therapy) III |
| 2:45 PM – 4:00 PM CST
|
|
|
|
|
Adverse Events Related to Darolutamide Treatment: Analysis of “Real Life” Data from EudraVigilance (EV) and the Food and Drug Administration (FDA) Database Entries
Presented By: Antonio Cicone
18F-DCFPyL PSMA PET Imaging Improves Detection of Nodal Metastases in Comparison to Conventional Imaging in Patients with Locally Advanced or Oligometastatic Prostate Cancer
Presented By: Ashanda Esdaille, MD
|
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer: Non-Invasive II |
| 8:45 AM – 10:00 AM CST
|
|
|
|
|
CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Presented By: Roger Li, MD
|
|
|
|
|
Longitudinal Health-Related Quality of Life Outcomes in Adults with Non-Muscle-Invasive Bladder Cancer Receiving a Chemoablative Gel as a Primary Treatment (Optima II: Phase 2b, single arm, open-label trial)
Presented By: Angela Smith, MD, MS
|
|
|
|
|
|
| Bladder Cancer: Upper Tract Transitional Cell Carcinoma II |
| 1:00 PM – 3:00 PM CST
|
|
|
|
|
Final Results of a Phase I Trial of WST11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma
Presented By: Wesley Yip, MD
|
|
|
|
|
Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube: a Multi-Institutional Real-World Experience
Presented By: Kyle Rose, MD
|
|
|
|
|
|
|
|
| New Orleans Restaurant Favorites - Plan Your AUA 2022 Dining Experiences |
Phillip Koo, MD, FACS and Oliver Sartor, MD
Drs Oliver Sartor and Phillip Koo explore the New Orleans restaurant scene in advance of the 2022 American Urological Association (AUA) annual meeting that takes place May 13-16. The 2022 meeting is the 117th meeting, providing unparalleled access to groundbreaking research, new guidelines, and the latest advances in urologic medicine. |
|
|
|
|
|
|
|
|
|
